🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,609 results for “AB” Clear

  1. Clazakizumab

    CSL Behring GmbH

    Antibody-mediated Rejection

    phase 3 mab terminated

    1 trial

  2. Clesrovimab

    Merck KGaA, Darmstadt, Germany

    Respiratory Syncytial Virus Infection

    phase 3 mab completed

    1 trial

  3. Clinical study to compare the therapeutic effects of two ointments with active substances betamethasone dipropionate and salicylic acid and of one ointment without active substances for patients with chronic stable plaque poriasis

    Alphapharm Pty Ltd

    Chronic stable plaque psoriasis

    phase 3 other active

    1 trial

  4. Clonidine HCL

    BRIGHT MINDS BIOSCIENCES INC.

    Neonatal Abstinence Syndrome

    phase 3 small molecule completed

    2 trials

  5. Clonidine HCl Mucoadhesive Buccal Tablet

    Monopar Therapeutics

    Chemoradiotherapy-Induced Severe Oral Mucositis

    phase 3 small molecule terminated

    1 trial

  6. Co-Trimoxazole 960Mg Dispersible Tablet

    United Therapeutics Europe Ltd

    Spontaneous Bacterial Peritonitis

    phase 3 small molecule active

    1 trial

  7. Coagulation Factor VIIa (Recombinant)

    Laboratoire HRA Pharma

    Hemophilia

    phase 3 mab terminated

    1 trial

  8. Cognitive Behavioral Therapy

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Abuse

    phase 3 other completed

    1 trial

  9. Combination Treatment of PDS0101 and Pembrolizumab

    PDS Biotechnology Corp

    Recurrent Head and Neck Cancer

    phase 3 other active

    1 trial

  10. Commercially available 0,9 % sterile saline solution with marketing authorization will be utilized as the placebo., KEYTRUDA 25 mg/mL concentrate for solution for infusion, INBRX-106, INBRX-106

    Inhibrx Biosciences

    Head and Neck Squamous Cell Carcinoma

    phase 3 small molecule active

    1 trial

  11. Concizumab

    Novo Nordisk A/S

    Haemophilia A With Inhibitors

    phase 3 small molecule active

    1 trial

  12. Concizumab

    Novo Nordisk A/S

    Haemophilia A Without Inhibitors

    phase 3 small molecule active

    1 trial

  13. Concizumab C 100 mg/mL PDS290, Concizumab C 40 mg/mL PDS290

    NovoThirteen

    haemophilia A (HA) with inhibitors and haemophilia B (HB) with inhibitors

    phase 3 small molecule active

    1 trial

  14. Concizumab C 100 mg/mL PDS290, Concizumab C 40 mg/mL PDS290, Concizumab C 10 mg/mL PDS290

    NovoThirteen

    Haemophilia A or B with or without inhibitors

    phase 3 small molecule active

    1 trial

  15. Concizumab C 40 mg/mL PDS290, Concizumab C 100 mg/mL PDS290

    NovoThirteen

    haemophilia A (HA) without inhibitors and haemophilia B (HB) without inhibitors

    phase 3 small molecule active

    1 trial

  16. Copiktra 25 mg hard capsules, Copiktra 15 mg hard capsules, DUVELISIB , BENDAMUSTINE , GEMCITABINE

    Secura Bio Limited

    relapsed/refractory nodal T cell lymphoma with T follicular helper (TFH) phenotype, relapsed/refractory nodal T cell lymphoma with T follicular helper (TFH) phenotype

    phase 3 small molecule active

    1 trial

  17. Coronary Artery Bypass Graft with the use of CPB

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    the Efficacy and Safety of Off-pump CABG

    phase 3 other completed

    1 trial

  18. Crenezumab

    Hoffmann-La Roche

    Alzheimer's Disease

    phase 3 small molecule terminated

    1 trial

  19. Crovalimab

    Hoffmann-La Roche

    Paroxysmal Nocturnal Hemoglobinuria

    phase 3 small molecule active

    1 trial

  20. Crovalimab

    Hoffmann-La Roche

    Atypical Hemolytic Uremic Syndrome (aHUS)

    phase 3 small molecule active

    1 trial

  21. Crovalimab, Crovalimab

    Hoffmann-La Roche

    Atypical Hemolytic Uremic Syndrome (aHUS)

    phase 3 small molecule active

    1 trial

  22. Crovalimab, ECULIZUMAB, Crovalimab

    Hoffmann-La Roche

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 3 small molecule active

    1 trial

  23. Cytarabine

    The First People's Hospital of Lianyungang

    Leukemia

    phase 3 small molecule active

    1 trial

  24. Cytarabine

    Jazz Pharmaceuticals Ireland Limited

    Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources